Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$12.7M Sell
50,502
-109,260
-68% -$23.5M 0.17% 93
2026
Q1
$34.7M Buy
159,762
+98,852
+162% +$21.9M 0.61% 30
2025
Q4
$13.9M Buy
60,910
+28,560
+88% +$6.51M 0.28% 53
2025
Q3
$7.49M Sell
32,350
-246,449
-88% -$50.2M 0.1% 149
2025
Q2
$51.8M Buy
278,799
+230,317
+475% +$42.8M 0.58% 33
2025
Q1
$10.2M Buy
48,482
+9,075
+23% +$1.76M 0.14% 93
2024
Q4
$7M Sell
39,407
-265,681
-87% -$48.8M 0.12% 116
2024
Q3
$60.2M Buy
305,088
+246,716
+423% +$46M 1.16% 21
2024
Q2
$10M Sell
58,372
-301
-0.5% -$49.9K 0.19% 76
2024
Q1
$10.7M Sell
58,673
-531
-0.9% -$91.5K 0.19% 90
2023
Q4
$9.17M Buy
59,204
+6,243
+12% +$910K 0.15% 95
2023
Q3
$7.89M Buy
52,961
+17,934
+51% +$2.63M 0.14% 101
2023
Q2
$4.72M Sell
35,027
-2,731
-7% -$400K 0.08% 136
2023
Q1
$6.02M Sell
37,758
-3,124
-8% -$478K 0.13% 122
2022
Q4
$6.61M Sell
40,882
-136,143
-77% -$20.9M 0.17% 98
2022
Q3
$23.8M Buy
177,025
+19,885
+13% +$2.85M 0.69% 36
2022
Q2
$24.1M Sell
157,140
-133,452
-46% -$20.4M 0.72% 37
2022
Q1
$47.1M Sell
290,592
-71,779
-20% -$10.4M 1.23% 19
2021
Q4
$49.1M Buy
362,371
+222,572
+159% +$26.3M 1.29% 19
2021
Q3
$15.1M Sell
139,799
-10,526
-7% -$1.2M 0.43% 48
2021
Q2
$17.5M Sell
150,325
-164,871
-52% -$18.6M 0.47% 50
2021
Q1
$34.1M Buy
315,196
+202,136
+179% +$21.6M 1.06% 21
2020
Q4
$12.1M Sell
113,060
-3,242
-3% -$312K 0.42% 56
2020
Q3
$10.2M Buy
116,302
+82,665
+246% +$7.78M 0.43% 39
2020
Q2
$3.3M Buy
33,637
+850
+3% +$74.8K 0.21% 93
2020
Q1
$2.5M Buy
32,787
+30,845
+1,588% +$2.63M 0.17% 109
2019
Q4
$172K Sell
1,942
-24,246
-93% -$2.01M 0.01% 325
2019
Q3
$1.98M Buy
26,188
+25,114
+2,338% +$1.72M 0.14% 118
2019
Q2
$78K Buy
+1,074
New +$84.4K 0.01% 391
2019
Q1
Sell
-7,505
Closed -$692K 271
2018
Q4
$692K Buy
+7,505
New +$660K 0.1% 128

Other funds holding ABBV

Ossiam's ABBV Position: Q2 2026 in Review

Ossiam reduced its AbbVie (ABBV) stake by 68% in Q2 2026, selling an estimated $23.5M and leaving 50,502 shares worth $12.7M. The position accounts for 0.17% of the portfolio, ranked #93.

Ossiam first reported a position in ABBV in Q4 2018 and has held it in 30 quarters since. The position peaked at $60.2M in Q3 2024. 4,188 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Ossiam held 50,502 shares of AbbVie worth $12.7M as of Q2 2026.
  • Ossiam sold 109,260 AbbVie shares in Q2 2026, an estimated $23.5M.
  • AbbVie made up 0.17% of Ossiam's portfolio in Q2 2026, its #93 holding.
  • Ossiam first reported a position in AbbVie in Q4 2018 and has held it in 30 quarters since.
  • Ossiam's AbbVie position peaked at $60.2M in Q3 2024.
  • 4,188 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Ossiam's 13F filing for Q2 2026, filed 13 Aug 2026.